imidafenacin

DRUG3 trials

Sponsors

LG Life Sciences, Astellas Pharma Singapore Pte. Ltd.

Conditions

Overactive BladderOveractive Bladder (OAB)

Phase 4

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

CompletedNCT01578304

LG Life SciencesOveractive Bladder

Start: 2010-12-31End: 2011-10-31Updated: 2012-04-16

Unknown Phase

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

CompletedNCT03572231

Astellas Pharma Singapore Pte. Ltd.Overactive Bladder (OAB)

Start: 2018-07-19End: 2020-03-30Updated: 2020-04-22

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

CompletedNCT03602508

Astellas Pharma Singapore Pte. Ltd.Overactive Bladder (OAB)

Start: 2018-07-20End: 2019-09-13Updated: 2024-10-16

Related Papers

Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).

2024-03-022 citations

A treatment prediction strategy for overactive bladder using a machine learning algorithm that utilized data from the FAITH study

Neurourology and Urodynamics2023-05-065 citations